Literature DB >> 27610018

Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma.

Chung-Tzu Hsueh1, Julie H Selim1, James Y Tsai1, Chung-Tsen Hsueh1.   

Abstract

Liposome, albumin and polymer polyethylene glycol are nanovector formulations successfully developed for anti-cancer drug delivery. There are significant differences in pharmacokinetics, efficacy and toxicity between pre- and post-nanovector modification. The alteration in clinical pharmacology is instrumental for the future development of nanovector-based anticancer therapeutics. We have reviewed the results of clinical studies and translational research in nanovector-based anti-cancer therapeutics in advanced pancreatic adenocarcinoma, including nanoparticle albumin-bound paclitaxel and nanoliposomal irinotecan. Furthermore, we have appraised the ongoing studies incorporating novel agents with nanomedicines in the treatment of pancreatic adenocarcinoma.

Entities:  

Keywords:  Biomarker; Nanoliposomal irinotecan; Nanoparticle albumin-bound paclitaxel; Nanovector; Pancreatic adenocarcinoma

Mesh：

Substances：

Year:  2016        PMID： 27610018      PMCID： PMC4988316          DOI： 10.3748/wjg.v22.i31.7080

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  58 in total

1.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

2.  Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.

Authors:  Paolo P Provenzano; Carlos Cuevas; Amy E Chang; Vikas K Goel; Daniel D Von Hoff; Sunil R Hingorani
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 4.  Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells.

Authors:  Michael Friberg Bruun Nielsen; Michael Bau Mortensen; Sönke Detlefsen
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

5.  Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients.

Authors:  Michael I Koukourakis; Alexandra Giatromanolaki; Rolf A Brekken; Efthimios Sivridis; Kevin C Gatter; Adrian L Harris; E Helene Sage
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

6.  nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

Authors:  Kristopher K Frese; Albrecht Neesse; Natalie Cook; Tashinga E Bapiro; Martijn P Lolkema; Duncan I Jodrell; David A Tuveson
Journal:  Cancer Discov       Date:  2012-02-28       Impact factor: 39.397

7.  A phase II trial of doxorubicin HCl Liposome Injection in patients with advanced pancreatic adenocarcinoma.

Authors:  G K Schwartz; E S Casper
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

8.  A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours.

Authors:  R Plummer; R H Wilson; H Calvert; A V Boddy; M Griffin; J Sludden; M J Tilby; M Eatock; D G Pearson; C J Ottley; Y Matsumura; K Kataoka; T Nishiya
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

9.  A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.

Authors:  A H Ko; M A Tempero; Y-S Shan; W-C Su; Y-L Lin; E Dito; A Ong; Y-W Wang; C G Yeh; L-T Chen
Journal:  Br J Cancer       Date:  2013-07-23       Impact factor: 7.640

10.  Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens.

Authors:  Chen Yang; Ying Liu; Wen-qi Xi; Chen-fei Zhou; Jin-ling Jiang; Tao Ma; Zheng-bao Ye; Jun Zhang; Zheng-gang Zhu
Journal:  Drug Des Devel Ther       Date:  2015-07-17       Impact factor: 4.162
View more
  5 in total

Review 1.  Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.

Authors:  Yvette N Lamb; Lesley J Scott
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

Review 2.  An Overview of the Importance of Transition-Metal Nanoparticles in Cancer Research.

Authors:  Olga Klaudia Szewczyk; Piotr Roszczenko; Robert Czarnomysy; Anna Bielawska; Krzysztof Bielawski
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

3.  Drug Loaded Gingival Mesenchymal Stromal Cells (GinPa-MSCs) Inhibit In Vitro Proliferation of Oral Squamous Cell Carcinoma.

Authors:  Valentina Coccè; Davide Farronato; Anna Teresa Brini; Carla Masia; Aldo Bruno Giannì; Giovanna Piovani; Francesca Sisto; Giulio Alessandri; Francesca Angiero; Augusto Pessina
Journal:  Sci Rep       Date:  2017-08-24       Impact factor: 4.379

4.  Cationic liposomes induce cytotoxicity in HepG2 via regulation of lipid metabolism based on whole-transcriptome sequencing analysis.

Authors:  Ying Li; Xiu-Liang Cui; Qing-Shan Chen; Jing Yu; Hai Zhang; Jie Gao; Du-Xin Sun; Guo-Qing Zhang
Journal:  BMC Pharmacol Toxicol       Date:  2018-07-11       Impact factor: 2.483

Review 5.  Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance.

Authors:  Michelle K Greene; Michael C Johnston; Christopher J Scott
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.